Current Status of Cord Blood Transplantation in China
Chen Yu-hong,Liu Kai-yan
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130627
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:In 1988, Gluckman performed the first cord blood transplant for a 5 year old boy with Fanconi anemia using a cord blood unit from the patient's unaffected sister.1 Patient remains alive and disease free for 24 years. Since then, extensive researches have established the safety and efficacy of umbilical cord blood transplantation (CBT) in both children and adults with a variety of malignant and non-malignant diseases. As of 2011, more than 25 000 CBTs have been performed. Compared with the unrelated bone marrow (UBM) or peripheral blood stem cells (UPBSC), unrelated cord blood (UCB) has many theoretical and clinical advantages: (1) non-invasive and easy procurement, with little risk to the mother or newborn; (2) expands donor pool for minorities targeted; (3) induces less frequent and less severe acute and chronic graft-versus-host disease (GVHD). These properties lead to less stringent HLA matching required; (4) availability for immediate access and use, according to Barker's report the median time to receiving UCB transplantation is 13.5 days, while the time for UBM is 50 days;2 (5) lower risk of transmitting infections by latent viruses. Actually, the clinical results of CBT, to date, are encouraging and appear at least comparable to bone marrow or peripheral blood progenitor cells as the donor source for transplants. The major patients receiving CBT are children. Eapen et al3 compared outcomes of 503 children (<16 years of age, 7% HLA allele matched ) with acute leukemia given an unrelated CBT (UCBT) with 282 unrelated BM transplant recipients (41% HLA allele matched). In comparison with allele-matched bone marrow transplants, the 5 year leukemia-free survival (LFS) was similar to transplants of CBT that was mismatched for either one or two HLA antigens. An HLA matched UCBT recipient had better outcomes compared to HLA allele matched BM recipients. However, an increased transplant related mortality (TRM) was observed in children transplanted with a low CB cell dose (<3×107/kg) and 1 HLA disparate CB graft or in children given a 2 HLA disparate UCBT independently of the cell dose infused. Interestingly, use of 2 HLA mismatched UCBT was associated with lower incidence of relapse resulted in comparable survival outcomes for this cohort.3 Now, in the pediatric setting, UCBT has become a standard of care in Europe and USA, in particular for the treatment of children with acute leukemia. In children, engraftment is consistently achieved (about 90%), with TRM ranges from 20% to 40%, and relapse and LFS ranging between 30% and 40%. Graft cell dose and HLA matching are critical determinants of TRM after single Unit CBT. In contrast to children, use of UCB in adults has been more restricted due to cell dose limitations. However, the similar studies were performed in adults with malignancies. For adults, the CD34+ cell dose is important. Laughlin et al found that a higher cryopreserved CD34+ cell dose (≥1.2×105/kg), was associated with a better EFS. The Eurocord study compared adults with acute leukemia receiving either a matched unrelated bone marrow transplant (n=584 HLA 6 out of 6) or a mismatched CBT (n=98). Results showed that, despite a delay of engraftment, CBT gave similar outcomes in terms of TRM, chronic GvHD, relapse rate and LFS between the two groups.4 More recently, Eapen and colleagues5 compared LFS in patients receiving cord blood, peripheral blood progenitor cells, or bone marrow transplantation in 1525 patients older than 16 years treated for acute leukemia between 2002 and 2005. CB recipients received a single unit containing a minimum of 2.5×107 total nucleated cells/kg at cryopreservation. CBT results, 94% receiving one or two antigen mismatches, were comparable to 8 of 8 or 7 of 8 allele-matched peripheral blood or marrow transplantation. TRM was higher with cord blood but acute and chronic GvHD incidence was lower than in those receiving peripheral blood. Chronic GvHD was lower with cord blood than marrow transplantation.5 Overall, these data support the use of CB as an alternative source of HSCs for patients who require a potentially curative allogeneic transplant but lack a suitable related donor or a matched unrelated donor. CBT has been carried out in several transplant centers in mainland China since the late 1990s. The papers in this issue are the display of the outcomes of CBT in China. The paper from Peking University People's Hospital has demonstrated that the outcomes of cord blood transplantation is comparable to bone marrow or peripheral blood stem cell transplants from unrelated donors in patients with hematologic malignancies. However, compared with the international advanced level, there is still much room for improvement. The cases of the CBT in China are comparative less. Most of the articles issued are summaries of the clinical data in a single center, lacking innovative and research on the mechanisms. There is no large scale of prospective multicenter data has been published. In order to promote the CBT in China, we need to focus on the following aspects. Increase the number of CBT especially in pediatric patients. A survey of the International Bone Marrow Transplant Registry (CIBMTR) shows that after 1998, 20% of stem cell transplants performed in young patients (<20 years old) are CBTs and the numbers of CBT in adults was exceeded the children since 2006 (IBMTR Newsletter). In Japan, nowadays approximately 50% of HSCT from unrelated donors are being performed with cord blood cells. However, due to the tremendous progress in the field of haploid identical transplant, which has completely solved the problem of sources of donor, the demand for CBT is not so urgent in China. This in turn hindered the impetus for further exploration in CBT. As of 2012, more than 590 000 cord blood units are stored in more than 100 quality controlled public banks worldwide. Among them, more than 50 000 cord blood units have been stored in China. Beijing cord blood bank has also fully accredited by the American Association of Blood Banks (AABB). According to the Eapen's report, better HLA matching significantly decrease the risk of TRM after CBT. Enough inventories can guarantee to find a more suitable umbilical cord blood to improve the outcome. But the number of CBT we transplant is actually far less than that proportion. The low utilization rate of cord blood restricts the development of CBT directly. Expand the indications for transplantation. Over the years, the use of CBT as a therapeutic modality has been extended to a variety of non-malignant disorders. Prasad et al6 summarized the outcomes of 159 young patients (median age of 1.5 years) with inherited metabolic disorders undergoing UCBT. All grafted patients, except three, achieved donor chimerism of greater than 90% and all but four engrafted patients sustained normal enzyme levels relating to each specific metabolic disease when measurable in the blood. The 1 year probability of overall survival was 77% in Hurler syndrome, 74% in Krabbe disease, 79% in Sanflippo syndrome, 65% in metachromatic leukodystrophy and 77% in adrenoleukodystrophy.6 Bizzetto et al7 reported in 2011 on 64 patients with hereditary bone marrow failure syndromes receiving CBTs from related and unrelated donors. By 60 days, 95% of related CBT and 55% of unrelated CBT achieved neutrophil engraftment. Overall survival at 3 years was 95% and 61% respectively.7 HLA compatibility is crucial for the survival of patients undergoing UCBT for non-malignant diseases. Liao et al8 from Guangzhou Women and Infants Hospital reported the results of CBT for 65 patients, including 16 patients had non-malignant disease. The data showed that the engraftment was relatively low in the non-malignant group compared with malignant patients (47% vs. 86%). So, CBT in the treatment of non-malignant diseases should be the future research field. Improve the results of the CBT. The disadvantages of CBT vs. BMT or PBSCT include (1) the fixed number of cells in a single UCB unit with a median of 1 ×109 total cells available, which may limit the use of UCB in overweight patients; (2) the delay in hematopoietic recovery and immune reconstitution with high rate of morbidity and mortality due to infections; and (3) the risk of graft failure that ranges from 5% to 15%. Various alternatives have been used to overcome these limitations, including coinfusion of two partially HLA-matched cord blood units. The first double CBT in China was performed by Peking University, People's Hospital in 2000. Unfortunately, the research did not continued thoroughly and further promoted. At the same time, the experts abroad have done a lot of work in this field. In fact, since 2005, the number of adult patients receiving double CBT has surpassed the number of adults transplanted with single cord blood units. The engraftment rate is comparable for both single and double umbilical cord blood transplantation; although the latter is accompanied by a higher incidence of grade II acute GvHD and lower leukemia relapse for patients in first complete remission. Several other possibilities are being investigated to improving the speed of HSCT engraftment and decreasing transplant related mortality: (1) increase the donor pool to decrease the number of HLA mismatches. In the small group of patients who received a 6/6 HLA matched cord blood transplant engraftment is improved, GVH is reduced and survival seems better compared to HLA matched unrelated BMT; (2) intrabone infusion shows better platelet engraftment and lower incidence of acute GvHD compared to IV infusion (3) expanding CB HSCs ex-vivo, and/or in vivo (4)enhancing homing and engrafting capabilities of obtained CB HSCs. Expand the transplant recipients by using novel conditioning regimen. Although the majority of the experiences with alternative donor reduce intensive conditioning (RIC) transplantation has been from peripheral stem cells (PBSC) or bone marrow (BM). In recent years, many groups have examined the use of UCB in this setting because of its immediate availability and permissible HLA disparity: Though there was initial concern that RIC would not be sufficient enough to allow engraftment of UCB grafts because of its reduced alloreactivity when compared to BM or PBSC, the first reports of RIC with UCBT were encouraging. Brunstein et al9 reported results in adults (n=110) transplanted for haematological disease with either one or two UCB units to achieve a minimum cell dose of 2×107 nucleated cells/kg. They reported a 92% incidence of sustained engraftment with 19% TRM and a 3-year OS of 45%, which is similar to those reported with other stem cell sources.9 Liu et al10 reported 18 patients with SAA who received RIC composed of CY (1200 mg/m2) +FLU (120 mg/m2+ATG (30 mg/kg). Fifteen patients experienced primary graft rejection, but all of them gained autologous recovery. The probability of OS at 2 years was 88.9%.10 The study is just preliminary, further controlled trials are needed to compare the results with immunosupression therapy. However, these data support the feasibility of RIC in CBT. Explore new use of umbilical cord blood stem cells. Except for transplantation, Cord blood stem cells or cells derived from cord blood stem cells can also been used to improve the recovery of hematopoietic or immunity reconstitution, to repair damaged tissue. In the study conducted by Zhou et al,11 25 patients with severe aplastic anemia were treated with ATG 2.5–3.0 mg·kg-1·d-1 × 5 d and cyclophosphamide CTX 50 mg·kg-1·d-1 × 2 d + cyclosporine A combined with an unrelated umbilical cord blood transfusion. After a median follow-up of 35 months, 18 of the 25 patients underwent a complete recovery. The overall efficacy rate was 88% and the 3-year overall survival rate was 92%. There was no durable donor engraftment.11 Therefore, great attention needs to be paid to the study of CBT, especially the research on umbilical cord blood stem cells, mechanism of CBT and the possibilities to improve the clinical results. The transplant centers also need to strengthen collaboration to carry out the prospective, multicenter clinical trials. We are in an exciting time in the area of CB biology and transplantation. Cord blood is an unlimited source of hematopoietic stem cells for allogeneic hematopoietic stem cell transplant. It has extended the availability of allogeneic HSCT to patients who would not otherwise be eligible for this curative approach. Many questions remain unanswered, but hopefully we are heading in the right direction.